Myriad Genetics announces results from myRisk studies to be featured at ASCO
Myriad Genetics announced that results from two studies of the myRisk Hereditary Cancer test will be featured in presentations at the annual meeting of the American Society of Clinical Oncology, or ASCO. The key findings were that women with post-menopausal breast cancer had a high rate of inherited mutations in a range of cancer causing genes, and that overall this mutation rate did not diminish with age. In a separate study, panel testing did not appear to result in over-use of preventative surgery. The findings will be presented by research collaborators from Stanford University Cancer Institute and the University of Southern California Norris Comprehensive Cancer Center.